{
    "id": "dbpedia_1362_3",
    "rank": 51,
    "data": {
        "url": "https://timi.org/publications/",
        "read_more_link": "",
        "language": "en",
        "title": "Publications",
        "top_image": "https://timi.org/wp-content/uploads/2020/01/graph.png",
        "meta_img": "https://timi.org/wp-content/uploads/2020/01/graph.png",
        "images": [
            "https://i0.wp.com/timi.org/wp-content/uploads/2023/03/cropped-TIMI-heart.png?fit=428%2C702&ssl=1",
            "https://i0.wp.com/timi.org/wp-content/uploads/2020/01/graph.png?resize=740%2C538&ssl=1"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2019-10-18T21:30:09+00:00",
        "summary": "",
        "meta_description": "You may also search for publications by trial by visiting our trial index. For information on the entire TIMI Study Group publication library, contact our Academic Coordinator. Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment. Yang M, Kondo T, Anand IS, de Boer RA, Campbell RT,…",
        "meta_lang": "en",
        "meta_favicon": "https://i0.wp.com/timi.org/wp-content/uploads/2023/02/cropped-untitled.png?fit=32%2C32&ssl=1",
        "meta_site_name": "TIMI STUDY GROUP",
        "canonical_link": "https://timi.org/publications/",
        "text": "You may also search for publications by trial by visiting our trial index.\n\nClinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment. Yang M, Kondo T, Anand IS, de Boer RA, Campbell RT, Køber L, Lam CSP, Maggioni AP, Martinez FA, O’Meara E, Packer M, Sabatine MS, Kerr Saraiva JF, Shah SJ, Zannad F, Zile MR, Jhund PS, Solomon SD, McMurray JJV. Eur J Heart Fail. 2024 Aug 21. doi: 10.1002/ejhf.3417.\n\nThe Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results. O’Donoghue ML, Rosenson RS, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Murphy SA, Wang H, Wu Y, Shah T, Wang J, Wilmanski T, Sohn W, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. J Am Coll Cardiol. 2024 Aug 27;84(9):790-797. doi: 10.1016/j.jacc.2024.05.058.\n\nQuantitative and Radiological Assessment of Post-cardiac-Arrest Comatose Patients with Diffusion-Weighted Magnetic Resonance Imaging. Van Roy S, Hsu L, Ho J, Scirica BM, Fischer D, Snider SB, Lee JW. Neurocrit Care. 2024 Aug 20. doi: 10.1007/s12028-024-02087-y.\n\nTriglycerides: the past, the present, and the future. Braunwald E. Eur Heart J. 2024 Aug 20:ehae515. doi: 10.1093/eurheartj/ehae515.\n\nCharacteristics and Outcomes of Adults With Congenital Heart Disease in the Cardiac Intensive Care Unit. Keane RR, Carnicelli AP, Loriaux DB, Kendsersky P, Krasuski RA, Brown KM, Arps K, Baird-Zars V, Dixson JA, Echols E, Granger CB, Harrison RW, Kontos M, Newby LK, Park JG, Shah KS, Ternus BW, Van Diepen S, Katz JN, Morrow DA. JACC Adv. 2024 Jul 22;3(8):101077. doi: 10.1016/j.jacadv.2024.101077.\n\nISR vs De Novo Lesion Treatment During OCT-Guided PCI: Insights From the LightLab Initiative. Bergmark BA, Golomb M, Kuder JF, Buccola J, Wollmuth J, Lopez J, Rauch J, Chehab BM, Rapoza R, West NEJ, Croce KJ. J Soc Cardiovasc Angiogr Interv. 2023 Aug 12;2(6Part A):101118. doi: 10.1016/j.jscai.2023.101118.\n\nOn the brink of the new year, on the brink of a new era: European Heart Journal Acute CardioVascular Care goes online only. Vranckx P, Morrow D, Verbrugge F. Eur Heart J Acute Cardiovasc Care. 2023 Jan 27;12(1):1.\n\nResponse to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial. Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Clin Cardiol. 2023 Jan 24. doi: 10.1002/clc.23972.\n\nMulti-Marker Risk Assessment in Patients Hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Bhatt AS, Daniels LB, de Lemos J, Goodrich E, Bohula EA, Morrow DA. Am Heart J. 2023 Jan 17:S0002-8703(22)00334-9. doi: 10.1016/j.ahj.2022.12.014.\n\nOCT utilization: Summary statistics from the LightLab clinical initiative. Raja A, Osborn EA, Bergmark BA, Croce KD, Poulin MF, Tamez H, West N, Buccola J, Meinen J, Secemsky EA; LightLab Clinical Initiative Investigators. Catheter Cardiovasc Interv. 2022 Nov;100 Suppl 1:S36-S43.\n\nHigh-Sensitivity Cardiac Troponin Assays in U.S. Hospitals: A Report Card. Gulati M, Berg DD. J Am Coll Cardiol. 2023 Jan 24;81(3):220-223.\n\nShort interfering RNA: a rapidly developing drug class. Braunwald E. Eur Heart J. 2022 Dec 7;43(46):4772-4774.\n\nControl of residual dyslipidaemic risk. Braunwald E. Eur Heart J. 2022 Oct 14;43(39):3824-3825.\n\nAir pollution: challenges and opportunities for cardiology. Braunwald E. Eur Heart J. 2023 Jan 7:ehac791. doi: 10.1093/eurheartj/ehac791.\n\nBridging Strategies and Cardiac Replacement Outcomes in Patients with Acute Decompensated Heart Failure-Related Cardiogenic Shock. Varshney AS, Berg DD, Zhou G, Sinnenberg L, Hirji S, DeFilippis EM, Mallidi HR, Morrow DA, Rinewalt D, Givertz MM. Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2762.\n\nIGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Drożdż J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Lindholm D, Hammarstedt A, Boulton DW, Greasley PJ, Langkilde AM, Solomon SD, Sattar N, McMurray JJV, Jhund PS. JACC Heart Fail. 2022 Oct 20:S2213-1779(22)00571-6. doi: 10.1016/j.jchf.2022.09.004.\n\nAcute cardiovascular care in the Emergency Department and beyond: A call for interdisciplinary collaboration in clinical research. Platz E, Morrow DA, Verbrugge FH, Vranckx P, Cullen L. Eur Heart J Acute Cardiovasc Care. 2022 Dec 31:zuac170. doi: 10.1093/ehjacc/zuac170.\n\nPredictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. Marston NA, Pirruccello JP, Melloni GEM, Koyama S, Kamanu FK, Weng LC, Roselli C, Kamatani Y, Komuro I, Aragam KG, Butterworth AS, Ito K, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. JAMA Cardiol. 2022 Dec 28. doi: 10.1001/jamacardio.2022.4466.\n\nPrognostic interpretation of serial high-sensitivity cardiac troponin in patients presenting with suspected acute coronary syndrome. Morrow DA. Eur Heart J. 2022 Dec 20:ehac749. doi: 10.1093/eurheartj/ehac749.\n\nCharacteristics, Therapies, and Outcomes of In-Hospital vs Out-of-Hospital Cardiac Arrest in Patients Presenting to Cardiac Intensive Care Units: From the Critical Care Cardiology Trials Network (CCCTN). Carnicelli AP, Keane R, Brown KM, Loriaux DB, Kendsersky P, Alviar CL, Arps K, Berg DD, Bohula EA, Burke JA, Dixson JA, Gerber DA, Goldfarb M, Granger CB, Guo J, Harrison RW, Kontos M, Lawler PR, Elliott Miller P, Nativi-Nicolau J, Kristin Newby L, Racharla L, Roswell RO, Shah KS, Sinha SS, Solomon MA, Teuteberg J, Wong G, van Diepen S, Katz JN, Morrow DA. Resuscitation. 2022 Dec 12:S0300-9572(22)00737-7. doi: 10.1016/j.resuscitation.2022.12.002.\n\nClinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. Popovic B, Ducrocq G, Elbez Y, Bode C, Mehta SR, Pollack CV, Sabate M, Rao SV, Parkhomenko A, Feldman LJ, Sayah N, Sabatine MS, Steg PG; TAO investigators. Am J Cardiol. 2022 Dec 6;188:95-101. doi: 10.1016/j.amjcard.2022.11.013.\n\nDiscovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, Venegas LM, Sherliker P, Koyama S, Ishigaki K, Åsvold BO, Brown MR, Brumpton B, de Vries PS, Giannakopoulou O, Giardoglou P, Gudbjartsson DF, Güldener U, Haider SMI, Helgadottir A, Ibrahim M, Kastrati A, Kessler T, Kyriakou T, Konopka T, Li L, Ma L, Meitinger T, Mucha S, Munz M, Murgia F, Nielsen JB, Nöthen MM, Pang S, Reinberger T, Schnitzler G, Smedley D, Thorleifsson G, von Scheidt M, Ulirsch JC; Biobank Japan; EPIC-CVD, Arnar DO, Burtt NP, Costanzo MC, Flannick J, Ito K, Jang DK, Kamatani Y, Khera AV, Komuro I, Kullo IJ, Lotta LA, Nelson CP, Roberts R, Thorgeirsson G, Thorsteinsdottir U, Webb TR, Baras A, Björkegren JLM, Boerwinkle E, Dedoussis G, Holm H, Hveem K, Melander O, Morrison AC, Orho-Melander M, Rallidis LS, Ruusalepp A, Sabatine MS, Stefansson K, Zalloua P, Ellinor PT, Farrall M, Danesh J, Ruff CT, Finucane HK, Hopewell JC, Clarke R, Gupta RM, Erdmann J, Samani NJ, Schunkert H, Watkins H, Willer CJ, Deloukas P, Kathiresan S, Butterworth AS; CARDIoGRAMplusC4D Consortium. Nat Genet. 2022 Dec;54(12):1803-1815. doi: 10.1038/s41588-022-01233-6.\n\nClinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry. Patel SM, Berg DD, Bohula EA, Baird-Zars VM, Barnett CF, Barsness GW, Chaudhry SP, Daniels LB, van Diepen S, Ghafghazi S, Goldfarb MJ, Jentzer JC, Katz JN, Kenigsberg BB, Lawler PR, Miller PE, Papolos AI, Park JG, Potter BJ, Prasad R, Singam NSV, Sinha SS, Solomon MA, Teuteberg JJ, Morrow DA; CCCTN Investigators. Circ Heart Fail. 2022 Dec 2:e009714. doi: 10.1161/CIRCHEARTFAILURE.122.009714.\n\nEfficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Pollack R, Raz I, Wiviott SD, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Mosenzon O, Langkilde AM, Gause-Nilsson IAM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Cahn A.\n\nDiabetes Care. 2022 Nov 18:dc221318. doi: 10.2337/dc22-1318.\n\nDecision-Making During Percutaneous Coronary Intervention Guided by Optical Coherence Tomography: Insights From the LightLab Initiative. Bergmark B, Dallan LAP, Pereira GTR, Kuder JF, Murphy SA, Buccola J, Wollmuth J, Lopez J, Spinelli J, Meinen J, West NEJ, Croce K; LightLab Initiative Investigators.\n\nCirc Cardiovasc Interv. 2022 Nov;15(11):872-881. doi: 10.1161/CIRCINTERVENTIONS.122.011851.\n\nPublisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries. Mishra A et. al. including Kamanu FK, Marston NA, Sabatine MS, Nature. 2022 Nov 14. doi: 10.1038/s41586-022-05492-5.\n\nPatient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P, Braunwald E, Sabatine MS. Eur Heart J. 2022 Nov 11:ehac402. doi: 10.1093/eurheartj/ehac402.\n\nThe Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock (ECMO-CS) Trial in Perspective. Morrow DA, van Diepen S. Eur Heart J Acute Cardiovasc Care. 2022 Nov 9:zuac145. doi: 10.1093/ehjacc/zuac145.\n\nResults of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network. Blood AJ, Cannon CP, Gordon WJ, Mailly C, MacLean T, Subramaniam S, Tucci M, Crossen J, Nichols H, Wagholikar KB, Zelle D, McPartlin M, Matta LS, Oates M, Aronson S, Murphy S, Landman A, Fisher NDL, Gaziano TA, Plutzky J, Scirica BM. JAMA Cardiol. 2022 Nov 9. doi: 10.1001/jamacardio.2022.4018.\n\nSex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER. Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ, Vardeny O, O’Meara E, Zieroth S, Katova T, McGrath MM, Pouleur AC, Jhund PS, Desai AS, Inzucchi SE, Kosiborod MN, de Boer RA, Køber L, Sabatine MS, Martinez FA, Ponikowski P, Shah SJ, Hernandez AF, Langkilde AM, McMurray JJV, Solomon SD, Lam CSP. Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062832.\n\nEffects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Docherty KF, Anand IS, Chiang CE, Chopra VK, Desai AS, Kitakaze M, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. JACC Asia. 2022 Mar 29;2(2):139-153. doi: 10.1016/j.jacasi.2022.02.004. eCollection 2022 Apr.\n\nSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. Michelle L O’Donoghue 1, Robert S Rosenson 1, Baris Gencer 1, J Antonio G López 1, Norman E Lepor 1, Seth J Baum 1, Elmer Stout 1, Daniel Gaudet 1, Beat Knusel 1, Julia F Kuder 1, Xinhui Ran 1, Sabina A Murphy 1, Huei Wang 1, You Wu 1, Helina Kassahun 1, Marc S Sabatine 1, OCEAN(a)-DOSE Trial Investigators. N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2211023.\n\nImpact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, MJ Landray, KJ Mayne, SYA Ng, D Preiss, AJ Roddick, N Staplin, D Zhu, SD Anker, DL Bhatt, M Brueckmann, J Butler, DZI Cherney, JB Green, SJ Hauske, HJL Heerspink, WG Herrington, SE Inzucchi, MJ Jardine, C-C Liu, KW Mahaffey, FR McCausland, DK McGuire, JJV McMurray, B Neal, BL Neuen, M Packer, V Perkovic, MS Sabatine, SD Solomon, M Vaduganathan, C Wanner, DC Wheeler, SD Wiviott, F Zannad. Lancet. 2022 Nov 19;400(10365):1788-1801.\n\nThe Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF, Granger C, Køber L, Maggioni A, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Ducrocq G, Berwanger O, De Pasquale CG, Landmesser U, Petrie M, Leng DSK, van der Meer P, Lefkowitz M, Zhou Y, Braunwald E. Circulation. 2022 Nov 2. doi: 10.1161/CIRCULATIONAHA.122.060841.\n\nOutcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Caso V, de Groot JR, Sanmartin Fernandez M, Segura T, Blomström-Lundqvist C, Hargroves D, Antoniou S, Williams H, Worsley A, Harris J, Caleyachetty A, Vardar B, Field P, Ruff CT. Heart. 2022 Oct 31:heartjnl-2022-321114. doi: 10.1136/heartjnl-2022-321114.\n\nGrowth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Kato ET, Morrow DA, Guo J, Berg DD, Blazing MA, Bohula EA, Bonaca MP, Cannon CP, de Lemos JA, Giugliano RP, Jarolim P, Kempf T, Kristin Newby L, O’Donoghue ML, Pfeffer MA, Rifai N, Wiviott SD, Wollert KC, Braunwald E, Sabatine MS. Eur Heart J. 2022 Oct 28:ehac577. doi: 10.1093/eurheartj/ehac577.\n\nPosition Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock. Damluji AA, Tehrani B, Sinha SS, Samsky MD, Henry TD, Thiele H, West NEJ, Senatore FF, Truesdell AG, Dangas GD, Smilowitz NR, Amin AP, deVore AD, Moazami N, Cigarroa JE, Rao SV, Krucoff MW, Morrow DA, Gilchrist IC. JACC Cardiovasc Interv. 2022 Oct 24;15(20):2003-2019.\n\nAtrial Fibrillation – What Is It and How Is It Treated? Antman EM, Leopold JA, Sauer WH, Zei PC. N Engl J Med. 2022 Oct 20;387(16):e38. doi: 10.1056/NEJMp2212939.\n\nAssociation of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT. Patel SM, Qamar A, Giugliano RP, Jarolim P, Marston NA, Park JG, Blazing MA, Cannon CP, Braunwald E, Morrow DA. JAMA Cardiol. 2022 Oct 19. doi: 10.1001/jamacardio.2022.3627. Online ahead of print.\n\nEffect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Cholesterol Treatment Trialists’ Collaboration. Meta-Analysis Lancet. 2022 Sep 10;400(10355):832-845. doi: 10.1016/S0140-6736(22)01545-8.\n\nOxygen Supplementation and Hyperoxia in Critically Ill Cardiac Patients: From Pathophysiology to Clinical Practice. Thomas A, van Diepen S, Beekman R, Sinha SS, Brusca SB, Alviar CL, Jentzer J, Bohula EA, Katz JN, Shahu A, Barnett C, Morrow DA, Gilmore EJ, Solomon MA, Miller PE.\n\nJACC Adv. 2022 Aug;1(3):100065. doi: 10.1016/j.jacadv.2022.100065.\n\nThe non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function – A systematic review. Huqi A, Zoccali C, Giugliano RP, Caterina R. Vascul Pharmacol. 2022 Oct 3:107123. doi: 10.1016/j.vph.2022.107123.\n\nAtrial Fibrillation and Catheter Ablation. Antman EM, Leopold JA, Sauer WH, Zei PC. N Engl J Med. 2022 Oct 6;387(14):e31. doi: 10.1056/NEJMp2212526.\n\nStroke genetics informs drug discovery and risk prediction across ancestries. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, Shi M, He Y, Georgakis MK, Caro I, Krebs K, Liaw YC, Vaura FC, Lin K, Winsvold BS, Srinivasasainagendra V, Parodi L, Bae HJ, Chauhan G, Chong MR, Tomppo L, Akinyemi R, Roshchupkin GV, Habib N, Jee YH, Thomassen JQ, Abedi V, Cárcel-Márquez J, Nygaard M, Leonard HL, Yang C, Yonova-Doing E, Knol MJ, Lewis AJ, Judy RL, Ago T, Amouyel P, Armstrong ND, Bakker MK, Bartz TM, Bennett DA, Bis JC, Bordes C, Børte S, Cain A, Ridker PM, Cho K, Chen Z, Cruchaga C, Cole JW, de Jager PL, de Cid R, Endres M, Ferreira LE, Geerlings MI, Gasca NC, Gudnason V, Hata J, He J, Heath AK, Ho YL, Havulinna AS, Hopewell JC, Hyacinth HI, Inouye M, Jacob MA, Jeon CE, Jern C, Kamouchi M, Keene KL, Kitazono T, Kittner SJ, Konuma T, Kumar A, Lacaze P, Launer LJ, Lee KJ, Lepik K, Li J, Li L, Manichaikul A, Markus HS, Marston NA, Meitinger T, Mitchell BD, Montellano FA, Morisaki T, Mosley TH, Nalls MA, Nordestgaard BG, O’Donnell MJ, Okada Y, Onland-Moret NC, Ovbiagele B, Peters A, Psaty BM, Rich SS, Rosand J, Sabatine MS, Sacco RL, Saleheen D, Sandset EC, Salomaa V, Sargurupremraj M, Sasaki M, Satizabal CL, Schmidt CO, Shimizu A, Smith NL, Sloane KL, Sutoh Y, Sun YV, Tanno K, Tiedt S, Tatlisumak T, Torres-Aguila NP, Tiwari HK, Trégouët DA, Trompet S, Tuladhar AM, Tybjærg-Hansen A, van Vugt M, Vibo R, Verma SS, Wiggins KL, Wennberg P, Woo D, Wilson PWF, Xu H, Yang Q, Yoon K; COMPASS Consortium; INVENT Consortium; Dutch Parelsnoer Initiative (PSI) Cerebrovascular Disease Study Group; Estonian Biobank; PRECISEQ Consortium; FinnGen Consortium; NINDS Stroke Genetics Network (SiGN); MEGASTROKE Consortium; SIREN Consortium; China Kadoorie Biobank Collaborative Group; VA Million Veteran Program; International Stroke Genetics Consortium (ISGC); Biobank Japan; CHARGE Consortium; GIGASTROKE Consortium, Millwood IY, Gieger C, Ninomiya T, Grabe HJ, Jukema JW, Rissanen IL, Strbian D, Kim YJ, Chen PH, Mayerhofer E, Howson JMM, Irvin MR, Adams H, Wassertheil-Smoller S, Christensen K, Ikram MA, Rundek T, Worrall BB, Lathrop GM, Riaz M, Simonsick EM, Kõrv J, França PHC, Zand R, Prasad K, Frikke-Schmidt R, de Leeuw FE, Liman T, Haeusler KG, Ruigrok YM, Heuschmann PU, Longstreth WT, Jung KJ, Bastarache L, Paré G, Damrauer SM, Chasman DI, Rotter JI, Anderson CD, Zwart JA, Niiranen TJ, Fornage M, Liaw YP, Seshadri S, Fernández-Cadenas I, Walters RG, Ruff CT, Owolabi MO, Huffman JE, Milani L, Kamatani Y, Dichgans M, Debette S. Nature. 2022 Sep 30. doi: 10.1038/s41586-022-05165-3.\n\nPublisher Correction: Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. Halford JL, Morrill VN, Choi SH, Jurgens SJ, Melloni G, Marston NA, Weng LC, Nauffal V, Hall AW, Gunn S, Austin-Tse CA, Pirruccello JP, Khurshid S, Rehm HL, Benjamin EJ, Boerwinkle E, Brody JA, Correa A, Fornwalt BK, Gupta N, Haggerty CM, Harris S, Heckbert SR, Hong CC, Kooperberg C, Lin HJ, Loos RJF, Mitchell BD, Morrison AC, Post W, Psaty BM, Redline S, Rice KM, Rich SS, Rotter JI, Schnatz PF, Soliman EZ, Sotoodehnia N, Wong EK; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Sabatine MS, Ruff CT, Lunetta KL, Ellinor PT, Lubitz SA. Nat Commun. 2022 Sep 30;13(1):5767. doi: 10.1038/s41467-022-33534-z.\n\nA remote hypertension management program clinical algorithm. Nichols H, Cannon CP, Scirica BM, Fisher NDL. Clin Cardiol. 2022 Sep 24. doi: 10.1002/clc.23919.\n\nInhibitors of factor XI: game changers of anti-thrombotic therapy. Braunwald E. Eur Heart J. 2022 Sep 23:ehac524. doi: 10.1093/eurheartj/ehac524.\n\nMortality and Heart Failure Hospitalization Among Young Adults With and Without Cardiogenic Shock after Acute Myocardial Infarction. Siddiqi HK, DeFilippis EM, Biery DW, Singh A, Wu WY, Divakaran S, Berman A, Rizk T, Januzzi JL, Bohula E, Stewart G, Carli MD, Bhatt DL, Blankstein R. J Card Fail. 2022 Sep 18:S1071-9164(22)00710-2. doi: 10.1016/j.cardfail.2022.08.012.\n\nBlood pressure and oxygenation targets after out-of-hospital cardiac arrest-trial (BOX). van Diepen S, Tavazzi G, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2022 Sep 15:zuac109. doi: 10.1093/ehjacc/zuac109.\n\nOxygenation targets in post-resuscitation care: a perspective of the BOX randomized clinical trial. Tavazzi G, van Diepen S, Morrow D. Eur Heart J Acute Cardiovasc Care. 2022 Sep 12:zuac110. doi: 10.1093/ehjacc/zuac110.\n\nA randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methods. Wronski ML, Plessow F, Kerem L, Asanza E, O’Donoghue ML, Stanford FC, Bredella MA, Torriani M, Soukas AA, Kheterpal A, Eddy KT, Holmes TM, Deckersbach T, Vangel M, Holsen LM, Lawson EA. Contemp Clin Trials. 2022 Sep 7:106909. doi: 10.1016/j.cct.2022.106909.\n\nMicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia. McCoy MG, Jamaiyar A, Sausen G, Cheng HS, Pérez-Cremades D, Zhuang R, Chen J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. Angiogenesis. 2022 Sep 8. doi: 10.1007/s10456-022-09856-3.\n\nLiver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. Adamson C, Cowan LM, de Boer RA, Diez M, Drożdż J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Lindholm D, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV, Jhund PS. Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2649.\n\nSacubitril/Valsartan Versus Ramipril For Patients With Acute Myocardial Infarction: Win-Ratio Analysis of the PARADISE_MI Trial. Berwanger O, Pfeffer M, Claggett B, Jering KS, Maggioni AP, Steg PG, Mehran R, Lewis EF, Zhou Y, van der Meer P, De Pasquale C, Merkely B, Filippatos G, McMurray JJV, Granger CB, Solomon SD, Braunwald E. Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2663.\n\nI2b2-etl: Python application for importing Electronic Health Data into the Informatics for Integrating Biology and the Bedside Platform. Wagholikar KB, Ainsworth L, Zelle D, Chaney K, Mendis M, Klann J, Blood AJ, Miller A, Chulyadyo R, Oates M, Gordon WJ, Aronson SJ, Scirica BM, Murphy SN. Bioinformatics. 2022 Sep 2:btac595. doi: 10.1093/bioinformatics/btac595.\n\nEndophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. Halford JL, Morrill VN, Choi SH, Jurgens SJ, Melloni G, Marston NA, Weng LC, Nauffal V, Hall AW, Gunn S, Austin-Tse CA, Pirruccello JP, Khurshid S, Rehm HL, Benjamin EJ, Boerwinkle E, Brody JA, Correa A, Fornwalt BK, Gupta N, Haggerty CM, Harris S, Heckbert SR, Hong CC, Kooperberg C, Lin HJ, Loos RJF, Mitchell BD, Morrison AC, Post W, Psaty BM, Redline S, Rice KM, Rich SS, Rotter JI, Schnatz PF, Soliman EZ, Sotoodehnia N, Wong EK; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Sabatine MS, Ruff CT, Lunetta KL, Ellinor PT, Lubitz SA. Nat Commun. 2022 Aug 30;13(1):5106. doi: 10.1038/s41467-022-32009-5.\n\nRandomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B. Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Murphy SA, Spinar J, Oude Ophuis T, Kiss RG, Lopez-Sendon J, Averkov O, Wheatcroft SB, Kubica J, Carlos Nicolau J, Furtado RHM, Abuhatzira L, Hirshberg B, Omar SA, Vavere AL, Chang YT, George RT, Sabatine MS. Circulation. 2022 Aug 30:101161CIRCULATIONAHA122059325. doi: 10.1161/CIRCULATIONAHA.122.059325.\n\nAnticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT. Bohula EA, Berg DD, Lopes MS, Connors JM, Babar I, Barnett CF, Chaudhry SP, Chopra A, Ginete W, Ieong MH, Katz JN, Kim EY, Kuder JF, Mazza E, McLean D, Mosier JM, Moskowitz A, Murphy SA, O’Donoghue ML, Park JG, Prasad R, Ruff CT, Shahrour MN, Sinha SS, Wiviott SD, Van Diepen S, Zainea M, Baird-Zars V, Sabatine MS, Morrow DA. Circulation. 2022 Aug 29. doi: 10.1161/CIRCULATIONAHA.122.061533.\n\nLong-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech AC, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. Circulation. 2022 Aug 29. doi: 10.1161/CIRCULATIONAHA.122.061620.\n\nDapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV. Nat Med. 2022 Aug 27. doi: 10.1038/s41591-022-01971-4.\n\nCritical Care Cardiology Trials Network (CCCTN): a cohort profile. Metkus TS, Baird-Zars VM, Alfonso CE, Alviar CL, Barnett CF, Barsness GW, Berg DD, Bertic M, Bohula EA, Burke J, Burstein B, Chaudhry SP, Cooper HA, Daniels LB, Fordyce CB, Ghafghazi S, Goldfarb M, Katz JN, Keeley EC, Keller NM, Kenigsberg B, Kontos MC, Kwon Y, Lawler PR, Leibner E, Liu S, Menon V, Miller PE, Newby LK, O’Brien CG, Papolos AI, Pierce MJ, Prasad R, Pisani B, Potter BJ, Roswell RO, Sinha SS, Shah KS, Smith TD, Snell RJ, So D, Solomon MA, Ternus BW, Teuteberg JJ, van Diepen S, Zakaria S, Morrow DA. Eur Heart J Qual Care Clin Outcomes. 2022 Aug 27:qcac055. doi: 10.1093/ehjqcco/qcac055.\n\nPredicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. Kondo T, Abdul-Rahim AH, Talebi A, Abraham WT, Desai AS, Dickstein K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Packer M, Petrie M, Ponikowski P, Rouleau JL, Sabatine MS, Swedberg K, Zile MR, Solomon SD, Jhund PS, McMurray JJ. Eur Heart J. 2022 Aug 26:ehac487. doi: 10.1093/eurheartj/ehac487.\n\nEvaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. Patel SM, Palazzolo MG, Murphy SA, Antman EM, Braunwald E, Lanz HJ, Lip GYH, Giugliano RP, Ruff CT. Europace. 2022 Aug 26:euac082. doi: 10.1093/europace/euac082.\n\nBiomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. Fagundes A Jr, Morrow DA, Oyama K, Furtado RHM, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Keech AC, Sever P, Giugliano RP, Sabatine MS, Bergmark BA. J Am Coll Cardiol. 2022 Aug 30;80(9):887-897. doi: 10.1016/j.jacc.2022.05.051.\n\nShort interfering RNA: a rapidly developing drug class. Braunwald E. Eur Heart J. 2022 Aug 25:ehac461. doi: 10.1093/eurheartj/ehac461.\n\nDapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes-Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, Rozenberg A, Murphy SA, Zelniker TA, Langkilde AM, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Wilding JPH, McGuire DK, Bhatt DL, Leiter LA, Cahn A, Dwyer JP, Heerspink HJL, Sabatine MS. Diabetes Care. 2022 Aug 23:dc220382. doi: 10.2337/dc22-0382.\n\nSafety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration? Huqi A, Zoccali C, Giugliano RP, De Caterina R. Eur Heart J. 2022 Aug 19:ehac450. doi: 10.1093/eurheartj/ehac450.\n\nA polygenic risk score predicts atrial fibrillation in cardiovascular disease. Marston NA, Garfinkel AC, Kamanu FK, Melloni GM, Roselli C, Jarolim P, Berg DD, Bhatt DL, Bonaca MP, Cannon CP, Giugliano RP, O’Donoghue ML, Raz I, Scirica BM, Braunwald E, Morrow DA, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT. Eur Heart J. 2022 Aug 18:ehac460. doi: 10.1093/eurheartj/ehac460.\n\nIron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Docherty KF, Welsh P, Verma S, De Boer RA, O’Meara E, Bengtsson O, Køber L, Kosiborod MN, Hammarstedt A, Langkilde AM, Lindholm D, Little DJ, Sjöstrand M, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Schou M, Solomon SD, Sattar N, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Circulation. 2022 Aug 16:101161CIRCULATIONAHA122060511. doi: 10.1161/CIRCULATIONAHA.122.060511.\n\nGlucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: 50 Years On and Time for a Relook. Udelson JE, Selker HP, Braunwald E. Circulation. 2022 Aug 16;146(7):503-505. doi: 10.1161/CIRCULATIONAHA.121.058740.\n\nCardiac Xenotransplantation: Another Historic First? Braunwald E. JACC Basic Transl Sci. 2022 Jul 25;7(7):743-744. doi: 10.1016/j.jacbts.2022.06.013.\n\nAnticipating Pharmacological Perturbation With Human Genetic Variation-Lessons From CETP. Natarajan P, Sabatine MS. JAMA Cardiol. 2022 Aug 3. doi: 10.1001/jamacardio.2022.2342.\n\nAtrial amyloidosis: mechanisms and clinical manifestations. Vergaro G, Aimo A, Rapezzi C, Castiglione V, Fabiani I, Pucci A, Buda G, Passino C, Lupón J, Bayes-Genis A, Emdin M, Braunwald E. Eur J Heart Fail. 2022 Aug 3. doi: 10.1002/ejhf.2650.\n\nCatheter-directed interventions for pulmonary embolism. Kochar A, Bergmark BA. Eur Heart J Acute Cardiovasc Care. 2022 Jul 29:zuac089. doi: 10.1093/ehjacc/zuac089.\n\nEffects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. Butt JH, Dewan P, DeFilippis EM, Biering-Sørensen T, Docherty KF, Jhund PS, Kosiborod MN, Martinez FA, Bengtsson O, Johansen ND, Langkilde AM, Sjöstrand M, Vaduganathan M, Solomon SD, Sabatine MS, Køber L, Fiuzat M, McMurray JJV. JACC Heart Fail. 2022 Aug;10(8):543-555. doi: 10.1016/j.jchf.2022.03.009.\n\nUse of automatic SQL generation interface to enhance transparency and validity of health-data analysis. Wagholikar KB, Zelle D, Ainsworth L, Chaney K, Blood AJ, Miller A, Chulyadyo R, Oates M, Gordon WJ, Aronson SJ, Scirica BM, Murphy SN. Inform Med Unlocked. 2022;31:100996. doi: 10.1016/j.imu.2022.100996.\n\nPatients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry. Fagundes A Jr, Berg DD, Park JG, Baird-Zars VM, Newby LK, Barsness GW, Miller PE, van Diepen S, Katz JN, Phreaner N, Roswell RO, Menon V, Daniels LB, Morrow DA, Bohula EA; CCCTN Investigators. Circ Cardiovasc Qual Outcomes. 2022 Jul 5:101161CIRCOUTCOMES121008652. doi: 10.1161/CIRCOUTCOMES.121.008652.\n\nEfficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Oyama K, Raz I, Cahn A, Goodrich EL, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. JAMA Cardiol. 2022 Jul 20. doi: 10.1001/jamacardio.2022.2006.\n\nEpidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Clin Cardiol. 2022 Jul 19. doi: 10.1002/clc.23843.\n\nThe Intersection between Heart Failure and Critical Care Cardiology: An International Perspective on Structure, Staffing, and Design Considerations. Sinha SS, Bohula EA, van Diepen S, Leonardi S, Mebazaa A, Proudfoot AG, Sionis A, Chia YW, Zampieri FG, Lopes RD, Katz JN. J Card Fail. 2022 Jul 14:S1071-9164(22)00579-6. doi: 10.1016/j.cardfail.2022.06.007.\n\nControl of residual dyslipidaemic risk. Braunwald E. Eur Heart J. 2022 Jul 5:ehac359. doi: 10.1093/eurheartj/ehac359.\n\nTolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In. Vader JM, Givertz MM, Starling RC, McNulty SE, Anstrom KJ, Desvigne-Nickens P, Hernandez AF, Braunwald E, Mann DL; LIFE Investigators. JACC Heart Fail. 2022 Jul;10(7):449-456.\n\nTime-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. J Clin Lipidol. 2022 Jun 6:S1933-2874(22)00174-X. doi: 10.1016/j.jacl.2022.05.069.\n\nLeaders in cardiovascular research: Eugene Braunwald. Braunwald E, Guzik TJ. Cardiovasc Res. 2022 Jun 22;118(7):e48-e50. doi: 10.1093/cvr/cvac033.\n\nBilirubin levels and kidney function decline: An analysis of clinical trial and real world data. Aoki Y, Cabrera CS, Ouwens M, Bamberg K, Nyström J, Raz I, Scirica BM, Hamrén B, Greasley PJ, Rekić D. PLoS One. 2022 Jun 21;17(6):e0269970. doi: 10.1371/journal.pone.0269970.\n\nGenetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies. Al. et O’Donoghue ML. Int. 2022 Jun 15:S0085-2538(22)00454-9. doi: 10.1016/j.kint.2022.05.021.\n\nRe-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, Green JB, Ruff CT, Sabatine MS. Clin Cardiol. 2022 Jun 17. doi: 10.1002/clc.23844.\n\nDifferential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. Al. et O’Donoghue ML. Commun Biol. 2022 Jun 13;5(1):580. doi: 10.1038/s42003-022-03448-z.\n\nP2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Capodanno D, Baber U, Bhatt DL, Collet JP, Dangas G, Franchi F, Gibson CM, Gwon HC, Kastrati A, Kimura T, Lemos PA, Lopes RD, Mehran R, O’Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey RF, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. Nat Rev Cardiol. 2022 Jun 13. doi: 10.1038/s41569-022-00725-6.\n\nProprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Schwartz GG, Giugliano RP. Curr Opin Lipidol. 2022 Jun 1;33(3):147-159. doi: 10.1097/MOL.0000000000000830.\n\nCardiac xenotransplantation: a new path for the treatment of advanced heart failure? Braunwald E. Eur Heart J. 2022 Jun 4:ehac276. doi: 10.1093/eurheartj/ehac276.\n\n“The Doctor Is Out”: New Tactics and Soldiers for Our Losing Battle Against Hypertension. Brook RD, Scirica BM, Levy PD. Circulation. 2022 May 31;145(22):1629-1631. doi: 10.1161/CIRCULATIONAHA.122.059674.\n\nGliflozins in the Management of Cardiovascular Disease. Braunwald E. N Engl J Med. 2022 May 26;386(21):2024-2034. doi: 10.1056/NEJMra2115011.\n\nMetabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF. Selvaraj S, Fu Z, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Newgard CB, Margulies KB, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Lanfear DE, Nassif ME, Javaheri A, Mentz RJ, Kosiborod MN, Shah SH. Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.122.060402.\n\nRelationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. Hofer F, Pailer U, Sulzgruber P, Gerges C, Winter MP, Giugliano RP, Gottsauner-Wolf M, Hülsmann M, Kazem N, Koller L, Schönbauer R, Niessner A, Hengstenberg C, Zelniker TA. ESC Heart Fail. 2022 May 20. doi: 10.1002/ehf2.13930.\n\nStudy Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial. O’Donoghue ML, López JAG, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MS. Am Heart J. 2022 May 6:S0002-8703(22)00086-2. doi: 10.1016/j.ahj.2022.05.004.\n\nLipoprotein(a) and its Significance in Cardiovascular Disease: A Review. Duarte Lau F, Giugliano RP. JAMA Cardiol. 2022 May 18. doi: 10.1001/jamacardio.2022.0987.\n\nSex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. Bikdeli B, Piazza G, Jimenez D, Muriel A, Wang Y, Khairani CD, Rosovsky RP, Mehdipoor G, O’Donoghue ML, Spagnolo P, Dreyer RP, Bertoletti L, López-Jiménez L, Núñez MJ, Blanco-Molina Á, Bates SM, Gerhard-Herman M, Goldhaber SZ, Monreal M, Krumholz HM. Thromb Res. 2022 May 4;214:122-131. doi: 10.1016/j.thromres.2022.04.019.\n\nEfficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Aylward P, Dalby AJ, Dellborg M, Dimulescu D, Nicolau JC, Oude Ophuis AJM, Cahn A, Mosenzon O, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Circulation. 2022 May 5. doi: 10.1161/CIRCULATIONAHA.121.058103.\n\nCould Neprilysin Be Already Inhibited by BNP in the LIFE Trial?-Reply. Mann DL, Hernandez AF, Braunwald E. JAMA Cardiol. 2022 May 4. doi: 10.1001/jamacardio.2022.0787.\n\nRelationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. Yeoh SE, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV. JACC Heart Fail. 2022 May;10(5):306-318. doi: 10.1016/j.jchf.2022.01.019.\n\nPrevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Gaba P, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Giugliano RP, Martens FMAC, Gibson CM, Ballantyne CM; REDUCE-IT Investigators. J Am Coll Cardiol. 2022 May 3;79(17):1660-1671. doi: 10.1016/j.jacc.2022.02.035.\n\nEvent Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States. Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. J Am Heart Assoc. 2022 Apr 27:e022198. doi: 10.1161/JAHA.121.022198.\n\nEpidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Bhatt AS, Varshney AS, Goodrich EL, Gong J, Ginder C, Senman BC, Johnson M, Butler K, Woolley AE, de Lemos JA, Morrow DA, Bohula EA. J Am Heart Assoc. 2022 Apr 26:e024451. doi: 10.1161/JAHA.121.024451.\n\nEfficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Butt JH, Dewan P, Merkely B, Belohlávek J, Drożdż J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Køber L, McMurray JJV. Ann Intern Med. 2022 Apr 26. doi: 10.7326/M21-4776.\n\nPMID: 35467935\n\nInitial Decline (“dip”) in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Vaduganathan M, Jhund PS, McMurray JJV. Circulation. 2022 Apr 20. doi: 10.1161/CIRCULATIONAHA.121.058910.\n\nCardiac cell therapy: a call for action. Braunwald E. Eur Heart J. 2022 Apr 13:ehac188. doi: 10.1093/eurheartj/ehac188.\n\nNovel three-stent strategy in left-main coronary artery trifurcation disease – Combination of DK crush and Culotte techniques. Sung JG, Kochar A, Croce KJ, Bergmark BA. Cardiovasc Revasc Med. 2022 Apr 2:S1553-8389(22)00172-5. doi: 10.1016/j.carrev.2022.03.034.\n\nNo association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. Korthauer LE, Giugliano RP, Guo J, Sabatine MS, Sever P, Keech A, Atar D, Kurtz C, Ruff CT, Mach F, Ott BR. PLoS One. 2022 Apr 11;17(4):e0266615. doi: 10.1371/journal.pone.0266615. eCollection 2022.\n\nSodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials. Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, Langkilde AM, Mahaffey KW, McGuire DK, Neal B, Perkovic V, Pong A, Sabatine MS, Raz I, Toyama T, Wanner C, Wheeler DC, Wiviott SD, Zinman B, Heerspink HJL. Circulation. 2022 Apr 8. doi: 10.1161/CIRCULATIONAHA.121.057736.\n\nAcute coronary syndromes. Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Lancet. 2022 Apr 2;399(10332):1347-1358. doi: 10.1016/S0140-6736(21)02391-6.\n\nPMID: 35367005 Free PMC article.\n\nEffect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Brian A. Bergmark, Nicholas A. Marston, Candace R. Bramson, Madelyn Curto, Vesper Ramos, Alexandra Jevne, Julia F. Kuder, Jeong-Gun Park, Sabina A. Murphy, Subodh Verma, Wojtek Wojakowski, Steven G. Terra, Marc S. Sabatine and Stephen D. Wiviott. Circulation. 3 Apr 2022. https://doi.org/10.1161/CIRCULATIONAHA.122.059266.\n\nSixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. Maron MS, Rosing DR, Braunwald E, Rastegar H, Koethe B, Roberts WC, Maron BJ, Rowin EJ. Am J Cardiol. 2022 Mar 28:S0002-9149(22)00180-1. doi: 10.1016/j.amjcard.2022.02.035.\n\nAntiplatelet therapy after percutaneous coronary intervention. Angiolillo DJ, Galli M, Collet JP, Kastrati A, O’Donoghue ML. EuroIntervention. 2022 Apr 1;17(17):e1371-e1396. doi: 10.4244/EIJ-D-21-00904.\n\nAppointment as patient advocacy associate editor. Vranckx P, Morrow D, Verbrugge F. Eur Heart J Acute Cardiovasc Care. 2022 Mar 15:zuac027. doi: 10.1093/ehjacc/zuac027.\n\nTreatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE‐IT Investigators. J Am Heart Assoc. 2022 Mar 9:e022937. doi: 10.1161/JAHA.121.022937.\n\nTirzepatide for diabetes: on track to SURPASS current therapy. Moura FA, Scirica BM, Ruff CT. Nat Med. 2022 Mar 8. doi: 10.1038/s41591-022-01733-2.\n\nIdeal Cardiovascular Health in Young Adults With Established Cardiovascular Diseases. Leopold JA, Antman EM. Front Cardiovasc Med. 2022 Feb 17;9:814610. doi: 10.3389/fcvm.2022.814610.\n\nChanging the Trajectory of Heart Failure and Kidney Disease. Rangaswami J, Bhalla V, Chertow G, Harrington R, Staruschenko A, Tuttle K, Braunwald E. Clin J Am Soc Nephrol. 2022 Mar 1:CJN.00470122. doi: 10.2215/CJN.00470122.\n\nEffects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. Scanavini-Filho MA, Berwanger O, Matthias W, Aguiar MO, Chiang HP, Azevedo L, Baracioli LM, Lima FG, Furtado RHM, Dalcoquio TF, Menezes FR, Ferrari AG, de Luca F, Giugliano RP, Goodman S, Nicolau JC. Adv Ther. 2022 Feb 26. doi: 10.1007/s12325-022-02061-0.\n\nEffect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Furtado RHM, Fagundes AA Jr, Oyama K, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BA. Circ Cardiovasc Interv. 2022 Feb 25:CIRCINTERVENTIONS121011382. doi: 10.1161/CIRCINTERVENTIONS.121.011382.\n\nNon-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. Giugliano RP. Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A1-A10. doi: 10.1093/eurheartj/suab150. eCollection 2022 Feb.\n\nTime for a paradigm shift? Making the case for tailored selection of antiplatelet therapy. O’Donoghue ML, Marston NA. Eur Heart J. 2022 Feb 15:ehac046. doi: 10.1093/eurheartj/ehac046.\n\nSodium and Health: Old Myths and a Controversy Based on Denial. Cappuccio FP, Campbell NRC, He FJ, Jacobson MF, MacGregor GA, Antman E, Appel LJ, Arcand J, Blanco-Metzler A, Cook NR, Guichon JR, L’Abbè MR, Lackland DT, Lang T, McLean RM, Miglinas M, Mitchell I, Sacks FM, Sever PS, Stampfer M, Strazzullo P, Sunman W, Webster J, Whelton PK, Willett W. Curr Nutr Rep. 2022 Feb 14. doi: 10.1007/s13668-021-00383-z.\n\nHeart failure: a 70 year Odyssey†. Braunwald E. Eur Heart J. 2022 Feb 15:ehac058. doi: 10.1093/eurheartj/ehac058.\n\nThe Road Not Yet Traveled: Distinction in Critical Care Cardiology through the Advanced Heart Failure and Transplant Cardiology Training Pathway. Carnicelli AP, Blumer V, Genovese L, Gage A, Agarwal R, Lakdawala NK, Bohula E, Katz JN. J Card Fail. 2022 Feb;28(2):339-342. doi: 10.1016/j.cardfail.2021.07.014.\n\nAngiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Reply.\n\nPfeffer MA, Jering KS, Braunwald E. N Engl J Med. 2022 Feb 10;386(6):603. doi: 10.1056/NEJMc2119225.\n\nA pragmatic lab-based tool for risk assessment in cardiac critical care: data from the Critical Care Cardiology Trials Network (CCCTN) Registry. Patel SM, Jentzer JC, Alviar CL, Baird-Zars VM, Barsness GW, Berg DD, Bohula EA, Daniels LB, DeFilippis AP, Keeley EC, Kontos MC, Lawler PR, Miller PE, Park JG, Roswell RO, Solomon MA, van Diepen S, Katz JN, Morrow DA.\n\nEur Heart J Acute Cardiovasc Care. 2022 Feb 3:zuac012. doi: 10.1093/ehjacc/zuac012.\n\nEffect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. Docherty KF, Simpson J, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Sjöstrand M, Lindholm D, Langkilde AM, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. JACC Heart Fail. 2022 Feb;10(2):104-118. doi: 10.1016/j.jchf.2021.09.002.\n\nCardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. Fordyce CB, Giugliano RP, Cannon CP, Roe MT, Sharma A, Page C, White JA, Lokhnygina Y, Braunwald E, Blazing MA. J Am Heart Assoc. 2022 Feb 3:e022733. doi: 10.1161/JAHA.121.022733.\n\nThe inclusion of augmented intelligence in medicine: A framework for successful implementation. Bazoukis G, Hall J, Loscalzo J, Antman EM, Fuster V, Armoundas AA. Cell Rep Med. 2022 Jan 18;3(1):100485. doi: 10.1016/j.xcrm.2021.100485. eCollection 2022 Jan 18.\n\nA call to action for translational sciences in COVID-19 and future pandemics. Wan KK, Davis D, Lee TN, Ford-Scheimer SL, Andreu AL, Bietrix F, Bryans J, Castro MT, Chiba N, Faupel-Badger JM, Haynes B, Hirasawa R, Morel CM, Souza TML, Morrow D, Munro T, Newman S, Ussi AE, Zorzal PB, Hall MD, Lo DC, Cutillo CM. Nat Rev Drug Discov. 2022 Jan 28. doi: 10.1038/d41573-022-00020-6.\n\nReply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. Oyama K, Giugliano RP, Sabatine MS, Cannon CP, Braunwald E. J Am Coll Cardiol. 2022 Feb 1;79(4):e153. doi: 10.1016/j.jacc.2021.11.018.\n\nUp in the Air. Loewenthal JV, Vaidya A, Duran B, Pozner CN, Scirica BM. N Engl J Med. 2022 Jan 27;386(4):e7. doi: 10.1056/NEJMimc2003326.\n\nAssociation of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski LA, Rijnders BJA, Rokx C, Sancho-Lopez A, Shaw P, Tebas P, Yoon HA, Grudzen C, Hochman J, Antman EM. JAMA Netw Open. 2022 Jan 4;5(1):e2147331. doi: 10.1001/jamanetworkopen.2021.47331.\n\nDevelopment and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. Park H, Tarpey T, Liu M, Goldfeld K, Wu Y, Wu D, Li Y, Zhang J, Ganguly D, Ray Y, Paul SR, Bhattacharya P, Belov A, Huang Y, Villa C, Forshee R, Verdun NC, Yoon HA, Agarwal A, Simonovich VA, Scibona P, Burgos Pratx L, Belloso W, Avendaño-Solá C, Bar KJ, Duarte RF, Hsue PY, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski LA, Rijnders BJA, Troxel A, Antman EM, Petkova E. JAMA Netw Open. 2022 Jan 4;5(1):e2147375. doi: 10.1001/jamanetworkopen.2021.47375.\n\nDapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. McDowell K, Welsh P, Docherty KF, Morrow DA, Jhund PS, De Boer RA, O’Meara E, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Hammarstedt A, Langkilde AM, Sjöstrand M, Lindholm D, Solomon SD, Sattar N, Sabatine MS, McMurray JJV. Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2433.\n\nEpidemiology of Acute Heart Failure in Critically Ill Patients with COVID-19: An Analysis from the Critical Care Cardiology Trials Network. Berg DD, Alviar CL, Bhatt AS, Baird-Zars VM, Barnett CF, Daniels LB, DeFilippis AP, Fagundes A Jr, Katrapati P, Kenigsberg BB, Guo J, Keller N, Lopes MS, Mody A, Papolos AI, Phreaner N, Sedighi R, Sinha SS, Toomu S, Varshney AS, Morrow DA, Bohula EA. J Card Fail. 2022 Jan 17:S1071-9164(22)00007-0. doi: 10.1016/j.cardfail.2021.12.020.\n\nClinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM, Gaedigk A, Caudle KE, Klein TE, Johnson JA, Shuldiner AR. Clin Pharmacol Ther. 2022 Jan 16. doi: 10.1002/cpt.2526.\n\nEffect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Kolkailah AA, Wiviott SD, Raz I, Murphy SA, Mosenzon O, Bhatt DL, Leiter LA, Wilding JPH, Gause-Nilsson I, Sabatine MS, McGuire DK. Diabetes Care. 2022 Jan 12:dc211668. doi: 10.2337/dc21-1668.\n\nMagnetic Resonance Spectroscopy of Hypoxic-Ischemic Encephalopathy After Cardiac Arrest. Lee JW, Sreepada L, Bevers M, Li K, Scirica B, Santana da Silva D, Henderson GV, Bay C, Lin AP. Neurology. 2022 Jan 11:10.1212/WNL.0000000000013297.\n\nRegional Distribution of Brain Injury After Cardiac Arrest: Clinical and Electrographic Correlates. Snider SB, Fischer D, McKeown ME, Cohen AL, Schaper FLWVJ, Amorim E, Fox MD, Scirica B, Bevers MB, Lee JW. Neurology. 2022 Jan 11:10.1212/WNL.0000000000013301.\n\nAssociation of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Raz I. Diabetes Care. 2022 Jan 10:dc211744. doi: 10.2337/dc21-1744.\n\nEdoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups. Gencer B, Eisen A, Berger D, Nordio F, Murphy SA, Grip LT, Chen C, Lanz H, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Am Heart J. 2022 Jan 3:S0002-8703(21)00499-3. doi: 10.1016/j.ahj.2021.12.017.\n\nRationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Am Heart J. 2022 Jan 2:S0002-8703(21)00483-X. doi: 10.1016/j.ahj.2021.12.010.\n\nEnd-of-life care in the cardiac intensive care unit: a contemporary view from the Critical Care Cardiology Trials Network (CCCTN) Registry. Fagundes A, Berg DD, Bohula EA, Baird-Zars VM, Barnett CF, Carnicelli AP, Chaudhry SP, Guo J, Keeley EC, Kenigsberg BB, Menon V, Miller PE, Newby LK, van Diepen S, Morrow DA, Katz JN. Eur Heart J Acute Cardiovasc Care. 2022 Jan 5:zuab121. doi: 10.1093/ehjacc/zuab121.\n\nDirect Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Bahit MC, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, Fox KA, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Kato ET, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB. Circulation. 2022 Jan 5. doi: 10.1161/CIRCULATIONAHA.121.056355.\n\nPractice Patterns in the Interventional Treatment of Coronary Bifurcation Lesions: A Global Survey. Nikolakopoulos I, Vemmou E, Karacsonyi J, Azzalini L, Bergmark BA, Chatzizisis YS, Hall AB, Wollmuth J, Croce K, Jneid H, Rangan BV, Burke MN, Brilakis ES. J Invasive Cardiol. 2022 Jan;34(1):E43-E48.\n\nEfficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O’Meara E, Verma S, Inzucchi SE, Køber L, Kosiborod MN, Lindholm D, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. JACC Heart Fail. 2022 Jan;10(1):52-64. doi: 10.1016/j.jchf.2021.08.006.\n\nIschemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. Bonaca MP, Antman EM, Cunningham JW, Wiviott SD, Murphy SA, Halperin JL, Weitz JI, Grosso MA, Lanz HJ, Braunwald E, Giugliano RP, Ruff CT. Eur Heart J Cardiovasc Pharmacother. 2021 Dec 28:pvab089. doi: 10.1093/ehjcvp/pvab089.\n\n2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Cardiovasc Comput Tomogr. 2021 Dec 1:S1934-5925(21)00469-X. doi: 10.1016/j.jcct.2021.11.009.\n\nHow to implement novel diagnostic algorithms for non-ST-segment elevation myocardial infarction in the emergency department. Cullen L, Mills NL, Morrow DA, Mueller C. Eur Heart J Acute Cardiovasc Care. 2021 Dec 18:zuab118. doi: 10.1093/ehjacc/zuab118.\n\nN-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort. O’Donnell C, Ashland MD, Vasti EC, Lu Y, Chang AY, Wang P, Daniels LB, de Lemos JA, Morrow DA, Rodriguez F, O’Brien CG. J Am Heart Assoc. 2021 Dec 10:e022913. doi: 10.1161/JAHA.121.022913.\n\nSubcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Nat Med. 2021 Dec 6. doi: 10.1038/s41591-021-01584-3.\n\nDapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-Rotter R, Toto RD, Wheeler DC, McMurray JJV, Heerspink HJL; DAPA-CKD and DAPA-HF Trial Committees and Investigators. Lancet Diabetes Endocrinol. 2021 Nov 29:S2213-8587(21)00295-3. doi: 10.1016/S2213-8587(21)00295-3.\n\nExploring patient experiences coping with using multiple medications: a qualitative interview study. Lauffenburger JC, Haff N, McDonnell ME, Solomon DH, Antman EM, Glynn RJ, Choudhry NK. BMJ Open. 2021 Nov 22;11(11):e046860. doi: 10.1136/bmjopen-2020-046860.\n\nElectronic Alerts to Initiate Anticoagulation Dialogue in Patients with Atrial Fibrillation. Antonio Gutierrez J, Ruff CT, Aday AW, Gu L, Schulteis RD, Shihai L, Petrini Pa-C M, Sun AY, Swaminathan RV, Katzenberger DR, Banerjee S, Rao SV. Am Heart J. 2021 Nov 19:S0002-8703(21)00452-X. doi: 10.1016/j.ahj.2021.11.008.\n\nContemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. Proudfoot AG, Kalakoutas A, Meade S, Griffiths MJD, Basir M, Burzotta F, Chih S, Fan E, Haft J, Ibrahim N, Kruit N, Lim HS, Morrow DA, Nakata J, Price S, Rosner C, Roswell R, Samaan MA, Samsky MD, Thiele H, Truesdell AG, van Diepen S, Voeltz MD, Irving PM. Circ Heart Fail. 2021 Nov 22. doi: 10.1161/CIRCHEARTFAILURE.121.008635.\n\nEfficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O’Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV, Køber L. Circ Heart Fail. 2021 Nov 22:CIRCHEARTFAILURE121008837. doi: 10.1161/CIRCHEARTFAILURE.121.008837.\n\nAssessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). Aoki Y, Hamrén B, Clegg LE, Stahre C, Bhatt DL, Raz I, Scirica BM, Oscarsson J, Carlsson B. PLoS One. 2021 Nov 19;16(11):e0259372. doi: 10.1371/journal.pone.0259372. eCollection 2021.\n\nImpact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, Fernandez A, Filippatos G, Jering K, Landmesser U, Menon V, Prof Merkely B, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Wang Y, Braunwald E. Circulation. 2021 Nov 19. doi: 10.1161/CIRCULATIONAHA.121.057429.\n\nPercutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, Kappetein AP, Park SJ, Park DW, Christiansen EH, Holm NR, Nielsen PH, Stone GW, Sabik JF, Braunwald E. Lancet. 2021 Nov 12:S0140-6736(21)02334-5. doi: 10.1016/S0140-6736(21)02334-5.\n\nThe European Heart Journal Acute Cardiovascular Care (EHJ ACVC) 2022: message from the editorial board. Vranckx P, Morrow D, Verbrugge F. Eur Heart J Acute Cardiovasc Care. 2021 Nov 10:zuab101. doi: 10.1093/ehjacc/zuab101.\n\nEpidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19 : A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Varshney AS, Omar WA, Goodrich EL, Bhatt AS, Wolley AE, Gong J, Senman BC, Silva D, Levangie MW, Berg DD, Yeh RW, de Lemos JA, Morrow DA, Kazi DS, Bohula EA. Circ Heart Fail. 2021 Nov 18: CIRCHEARTFAILURE121008477. doi: 10.1161/CIRCHEARTFAILURE.121.008477.\n\nCan machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. Rousset A, Dellamonica D, Menuet R, Lira Pineda A, Sabatine MS, Giugliano RP, Trichelair P, Zaslavskiy M, Ricci L. Eur Heart J. 2021 Nov 15. Doi:10.1093/ehjdz/tab093.\n\nAssociation of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, Ference B, Stein E, Stroes ES, Braunwald E, Ellinor PT, Lubitz SA, Ruff CT, Sabatine MS. JAMA Cardiol. 2021 Nov 13. doi: 10.1001/jamacardio.2021.5083.\n\nDapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF. Butt JH, Docherty KF, Jhund PS, De Boer RA, Böhm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC, Petrie MC, Ponikowski P, Bengtsson O, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, McMurray JJ, Køber L. Eur J Heart Fail. 2021 Nov 11. doi: 10.1002/ejhf.2381.\n\nWorkflow Automation for a Virtual Hypertension Management Program. Gordon WJ, Blood AJ, Chaney K, Clark E, Glynn C, Green R, Laurent JS, Mailly C, McPartlin M, Murphy S, Nichols H, Oates M, Subramaniam S, Varugheese M, Wagholikar K, Aronson S, Scirica BM. Appl Clin Inform. 2021 Oct;12(5):1041-1048. doi: 10.1055/s-0041-1739195. Epub 2021 Nov 10.\n\nAngiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E; PARADISE-MI Investigators and Committees. N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508.\n\n2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Am Coll Cardiol. 2021 Oct 23:S0735-1097(21)05795-8. doi: 10.1016/j.jacc.2021.07.053.\n\n2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Am Coll Cardiol. 2021 Oct 23:S0735-1097(21)05794-6. doi: 10.1016/j.jacc.2021.07.052.\n\nCardiogenic Shock After Acute Myocardial Infarction: A Review. Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. JAMA. 2021 Nov 9;326(18):1840-1850. doi: 10.1001/jama.2021.18323.\n\nSerial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, de Boer RA, Kosiborod MN, Nicolau JC, O’Meara E, Schou M, Hammarstedt A, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJV, Sabatine MS, Morrow DA. Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057852.\n\nSGLT2 inhibitors: the statins of the 21st century. Braunwald E. Eur Heart J. 2021 Nov 6:ehab765. doi: 10.1093/eurheartj/ehab765.\n\nInterpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. Berg DD, Kolkailah AA, Sarraju A, Kerchberger AM, Eljalby M, McGuire DK.\n\nCurr Diab Rep. 2021 Nov 6;21(11):45. doi: 10.1007/s11892-021-01417-0.\n\nEffect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. JAMA Cardiol. 2021 Nov 3. doi: 10.1001/jamacardio.2021.4567.\n\nHigh-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. David D Berg, Marc S Sabatine, Naveed Sattar, Petr Jarolim, Paul WELSH, Pardeep S Jhund, Inder Anand, Rudolf A De Boer, Mikhail Kosiborod, Eileen O’Meara, Ann Hammarstedt, Anna Maria Langkilde, Daniel Lindholm, Mikaela Sjöstrand, John J McMurray, David Morrow. Originally published 8 Nov 2021Circulation. 2021;144:A11692.\n\nIcosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Circulation. 2021 Oct 28. doi: 10.1161/CIRCULATIONAHA.121.056290.\n\n2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. Circulation. 2021 Oct 28:CIR0000000000001030. doi: 10.1161/CIR.0000000000001030.\n\n2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. Circulation. 2021 Oct 28:CIR0000000000001029. doi: 10.1161/CIR.0000000000001029.\n\nLEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Ruff CT, Koren MJ, Grimsby J, Rosenbaum AI, Tu X, Karathanasis SK, Falloon J, Hsia J, Guan Y, Conway J, Tsai LF, Hummer BT, Hirshberg B, Kuder J, Murphy SA, George RT, Sabatine MS. Arterioscler Thromb Vasc Biol. 2021 Oct 28:ATVBAHA120315757. doi: 10.1161/ATVBAHA.120.315757.\n\nLong-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Chapman KR, Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Lythgoe D, Gil EG. Respir Res. 2021 Oct 22;22(1):272. doi: 10.1186/s12931-021-01861-2.\n\nImproving prediction of anticoagulant-related major bleeding in atrial fibrillation: The search for new biomarkers. Berg DD, Morrow DA. J Thromb Haemost. 2021 Nov;19(11):2674-2676. doi: 10.1111/jth.15525.\n\nOutcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention. Paruchuri K, Finneran P, Marston NA, Healy EW, Andreo J Jr, Lynch R, Blood AJ, Jones-O’Connor M, Lander B, Kelly N, Vivaldi MT, Traynor K, Wiviott S, Natarajan P. EBioMedicine. 2021 Sep 15:103593. doi: 10.1016/j.ebiom.2021.103593.\n\nIn Memoriam: A Tribute to Attilio Maseri. Crea F, Braunwald E, Fuster V. J Am Coll Cardiol. 2021 Oct 7:S0735-1097(21)07176-X. doi: 10.1016/j.jacc.2021.10.001.\n\nDigital health device measured sleep duration and ideal cardiovascular health: an observational study. Leopold JA, Antman EM. BMC Cardiovasc Disord. 2021 Oct 14;21(1):497. doi: 10.1186/s12872-021-02284-z.\n\nA tribute to Attilio Maseri. Crea F, Braunwald E, Fuster V. Eur Heart J. 2021 Oct 12:ehab714. doi: 10.1093/eurheartj/ehab714.\n\nCardiac myosin-binding protein C as a biomarker of acute myocardial infarction. Marber MS, Mills NL, Morrow DA, Mueller C. Eur Heart J Acute Cardiovasc Care. 2021 Oct 11:zuab086. doi: 10.1093/ehjacc/zuab086.\n\nEfficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. Figueroa JM, Lombardo ME, Dogliotti A, Flynn LP, Giugliano R, Simonelli G, Valentini R, Ramos A, Romano P, Marcote M, Michelini A, Salvado A, Sykora E, Kniz C, Kobelinsky M, Salzberg DM, Jerusalinsky D, Uchitel O. Int J Gen Med. 2021 Oct 1;14:6277-6286. doi: 10.2147/IJGM.S328486.\n\nClosing the Gap: Insights into the Epidemiology of Heart Failure Care from the Critical Care Cardiology Trials Network. Morrow DA. J Card Fail. 2021 Oct;27(10):1146-1147.\n\nDe Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. Bhatt AS, Berg DD, Bohula EA, Alviar CL, Baird-Zars VM, Barnett CF, Burke JA, Carnicelli AP, Chaudhry SP, Daniels LB, Fang JC, Fordyce CB, Gerber DA, Guo J, Jentzer JC, Katz JN, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Nativi-Nicolau J, Phreaner N, Roswell RO, Sinha SS, Jeffrey Snell R, Solomon MA, Van Diepen S, Morrow DA. J Card Fail. 2021 Oct;27(10):1073-1081.\n\nThe Nexus of Heart Failure and Critical Care Cardiology. Sinha SS, Bohula EA, Katz JN. J Card Fail. 2021 Oct;27(10):1041.\n\nEfficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. Gilchrist IC Jr, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, Bonaca MP. J Am Heart Assoc. 2021 Oct 8:e021412.\n\nComparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Gaba P, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Ballantyne CM, Pinto DS, Budoff MJ, Gibson CM.J Am Coll Cardiol. 2021 Oct 12;78(15):1525-1537.\n\nBaseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald E. J Am Coll Cardiol. 2021 Oct 12;78(15):1499-1507.\n\nHeart failure with preserved ejection fraction: a stepchild no more! Braunwald E. Eur Heart J. 2021 Oct 7;42(38):3900-3901.\n\nRisk factors for type 2 MI: the usual suspects or guilt by association? O’Donoghue ML, Marston NA. Eur Heart J. 2021 Oct 2:ehab707. doi: 10.1093/eurheartj/ehab707.\n\nValsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators, Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Nat Med. 2021 Sep 23. doi: 10.1038/s41591-021-01505-4.\n\nManagement and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams. Papolos AI, Kenigsberg BB, Berg DD, Alviar CL, Bohula E, Burke JA, Carnicelli AP, Chaudhry SP, Drakos S, Gerber DA, Guo J, Horowitz JM, Katz JN, Keeley EC, Metkus TS, Nativi-Nicolau J, Snell JR, Sinha SS, Tymchak WJ, Van Diepen S, Morrow DA, Barnett CF; Critical Care Cardiology Trials Network Investigators. J Am Coll Cardiol. 2021 Sep 28;78(13):1309-1317. doi: 10.1016/j.jacc.2021.07.044.\n\nWalking the tightrope between ischaemia and bleeding. O’Donoghue ML, Patel SM. EuroIntervention. 2021 Sep 20;17(7):527-529. doi: 10.4244/EIJV17I7A93.\n\nA Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Berg DD, Wiviott SD, Scirica BM, Zelniker TA, Goodrich EL, Jarolim P, Mosenzon O, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Langkilde AM, Raz I, Braunwald E, Sabatine MS, Morrow DA. Diabetes Care. 2021 Sep 17:dc211170. doi: 10.2337/dc21-1170.\n\nEfficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Chuecos F, Garcia Gil E, Chapman KR. Adv Ther. 2021 Sep 15. doi: 10.1007/s12325-021-01878-5.\n\nEffect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Kazuma Oyama, Robert P Giugliano, Minao Tang, Marc P Bonaca, Jeffrey L Saver, Sabina A Murphy, Andrea Ruzza, Anthony C Keech, Peter S Sever, Marc S Sabatine, Brian A Bergmark. Eur Heart J. 2021 Sept 19; ehab604. doi: 10.1093/eurheartj/ehab604.\n\nInhibition of p38 MAP Kinase in Patients with ST-Elevation Myocardial Infarction – Findings from the LATITUDE TIMI 60 Trial. Cavender MA, O’Donoghue M, Abbate A, Aylward P, Fox KAA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA. Am Heart J. 2021 Sep 8:S0002-8703(21)00229-5. doi: 10.1016/j.ahj.2021.08.022.\n\nPopulation Health Identification and Management of Low Density Lipoprotein Cholesterol via a Remote, Algorithmic, Navigator-Executed Program. Plutzky J, Benson MD, Chaney K, Bui TV, Kraft M, Matta L, McPartlin M, Zelle D, Cannon CP, Dodek A, Gaziano TA, Desai AS, MacRae CA, Scirica BM. Am Heart J. 2021 Sep 2:S0002-8703(21)00223-4. doi: 10.1016/j.ahj.2021.08.017.\n\nThe genomics of heart failure: design and rationale of the HERMES consortium. Lumbers RT, Shah S, Lin H, Czuba T, Henry A, Swerdlow DI, Mälarstig A, Andersson C, Verweij N, Holmes MV, Ärnlöv J, Svensson P, Hemingway H, Sallah N, Almgren P, Aragam KG, Asselin G, Backman JD, Biggs ML, Bloom HL, Boersma E, Brandimarto J, Brown MR, Brunner-La Rocca HP, Carey DJ, Chaffin MD, Chasman DI, Chazara O, Chen X, Chen X, Chung JH, Chutkow W, Cleland JGF, Cook JP, de Denus S, Dehghan A, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Engström G, Esko T, Fatemifar G, Felix SB, Finan C, Ford I, Fougerousse F, Fouodjio R, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gui H, Gutmann R, Haggerty CM, van der Harst P, Hedman ÅK, Helgadottir A, Hillege H, Hyde CL, Jacob J, Jukema JW, Kamanu F, Kardys I, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Kraus B, Kuchenbaecker K, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Mann D, Margulies KB, Marston NA, März W, McMurray JJV, Melander O, Melloni G, Mordi IR, Morley MP, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP, Newton-Cheh C, Niessner A, Niiranen T, Nowak C, O’Donoghue ML, Owens AT, Palmer CNA, Paré G, Perola M, Perreault LL, Portilla-Fernandez E, Psaty BM, Rice KM, Ridker PM, Romaine SPR, Roselli C, Rotter JI, Ruff CT, Sabatine MS, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, Stefansson K, Stender S, Stott DJ, Sveinbjörnsson G, Tammesoo ML, Tardif JC, Taylor KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tuckwell D, Tyl B, Uitterlinden AG, Vaura F, Veluchamy A, Visscher PM, Völker U, Voors AA, Wang X, Wareham NJ, Weeke PE, Weiss R, White HD, Wiggins KL, Xing H, Yang J, Yang Y, Yerges-Armstrong LM, Yu B, Zannad F, Zhao F; Regeneron Genetics Center, Wilk JB, Holm H, Sattar N, Lubitz SA, Lanfear DE, Shah S, Dunn ME, Wells QS, Asselbergs FW, Hingorani AD, Dubé MP, Samani NJ, Lang CC, Cappola TP, Ellinor PT, Vasan RS, Smith JG. ESC Heart Fail. 2021 Sep 3. doi: 10.1002/ehf2.13517.\n\nCardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl. Marston NA, Giugliano RP, Park JG, Ruzza A, Sever PS, Keech AC, Sabatine MS. Circulation. 2021 Aug 27. doi: 10.1161/CIRCULATIONAHA.121.056536.\n\nEffect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV. Eur Heart J. 2021 Aug 27:ehab560. doi: 10.1093/eurheartj/ehab560.\n\nA new initiative of the European Heart Journal: the Desmond Julian Award. Crea F, Braunwald E. Eur Heart J. 2021 Aug 26:ehab535. doi: 10.1093/eurheartj/ehab535.\n\nAssessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply. Marcusa DP, Giugliano RP, Sabatine MS. JAMA Cardiol. 2021 Aug 25. doi: 10.1001/jamacardio.2021.3028.\n\nObesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Špinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Eur Heart J. 2021 Aug 24:ehab530. doi: 10.1093/eurheartj/ehab530.\n\nLong-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Špinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. J Am Heart Assoc. 2021 Aug 21:e020446. doi: 10.1161/JAHA.120.020446.\n\nProspective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. Giugliano RP, Gencer B, Wiviott SD, Park JG, Fuchs CS, Goessling W, Musliner TA, Tershakovec AM, Blazing MA, Califf R, Cannon CP, Braunwald E. JACC CardioOncol. 2020 Sep 15;2(3):385-396. doi: 10.1016/j.jaccao.2020.07.008. eCollection 2020 Sep.\n\nIncreasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives. Cho L, Vest AR, O’Donoghue ML, Ogunniyi MO, Sarma AA, Denby KJ, Lau ES, Poole JE, Lindley KJ, Mehran R; Cardiovascular Disease in Women Committee Leadership Council. J Am Coll Cardiol. 2021 Aug 17;78(7):737-751.\n\nAn overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. Antman EM, Freeman MW, Golan DE, Kitterman R, McKenna E, Parrish J, Vaughan C, Watts L, Loscalzo J. J Clin Transl Sci. 2021 May 17;5(1):e137.\n\nTransmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. Colaco NA, Wang TS, Ma Y, Scherzer R, Ilkayeva OR, Desvigne-Nickens P, Braunwald E, Hernandez AF, Butler J, Shah SH, Shah SJ, Hsue PY. J Am Heart Assoc. 2021 Aug 7:e020499. doi: 10.1161/JAHA.120.020499.\n\nA Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. Berg DD, Giugliano RP, Ruff CT, Tang M, Im K, Jarolim P, Rutman H, Antman EM, Braunwald E, Morrow DA. J Am Coll Cardiol. 2021 Aug 10;78(6):634-636. doi: 10.1016/j.jacc.2021.06.008.\n\nHow to live to 100 before developing clinical coronary artery disease: a suggestion. Braunwald E. Eur Heart J. 2021 Aug 6:ehab532. doi: 10.1093/eurheartj/ehab532.\n\nCholesterol: the race to the bottom. Braunwald E. Eur Heart J. 2021 Aug 2:ehab446. doi: 10.1093/eurheartj/ehab446.\n\nExtrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. JAMA Cardiol. 2021 Jul 28. doi: 10.1001/jamacardio.2021.2632.\n\nLDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O’Donoghue ML. Eur J Prev Cardiol. 2021 Jul 23;28(8):805-812.\n\nA precision medicine approach to sex-based differences in ideal cardiovascular health. Leopold JA, Antman EM. Sci Rep. 2021 Jul 21;11(1):14848.\n\nCombining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Marston NA, Oyama K, Jarolim P, Tang M, Sever PS, Keech AC, Lira Pineda A, Wang H, Giugliano RP, Sabatine MS, Morrow DA. Circulation. 2021 Jul 20;144(3):249-251.\n\nEfficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang CE, Diez M, Drożdż J, Dukát A, Howlett J, Ljungman CEA, Petrie MC, Schou M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJ. Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.\n\nEarly Aspirin Use, Allograft Rejection, and Cardiac Allograft Vasculopathy in Heart Transplantation. Bergmark BA, Zelniker TA, Kim M, Mehra MR, Stewart GC, Page DS, Woodcome EL, Givertz MM. Clin Transplant. 2021 Jul 13. doi: 10.1111/ctr.14424.\n\nThe Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. Diabetes Care. 2021 Jul 7:dc210076. doi: 10.2337/dc21-0076.\n\nIdeal Cardiovascular Health in Former Smokers. Leopold JA, Antman EM. J Clin Med. 2021 Jun 1;10(11):2450. doi: 10.3390/jcm10112450.\n\nReply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? Steffel J, Ruff CT, Antman EM, Braunwald E, Giugliano RP. J Am Coll Cardiol. 2021 Jun 29;77(25):3232-3233.\n\nMyocardial Infarction and Evolocumab-Reply. Wiviott SD, Giugliano RP, Sabatine MS. JAMA Cardiol. 2021 Jun 23. doi: 10.1001/jamacardio.2021.2000\n\nReflections on Hypertrophic Cardiomyopathy. Braunwald E. Eur Heart J. 2021 Jun 21:ehab337. doi: 10.1093/eurheartj/ehab337.\n\nPlatelet Reactivity and Coagulation Markers in Patients with COVID-19. Bertolin AJ, Dalçóquio TF, Salsoso R, de M Furtado RH, Kalil-Filho R, Hajjar LA, Siciliano RF, Kallás EG, Baracioli LM, Lima FG, Giraldez RR, Cavalheiro-Filho C, Vieira A, Strunz CMC, Giugliano RP, Tantry US, Gurbel PA, Nicolau JC. Adv Ther. 2021 Jun 4. doi: 10.1007/s12325-021-01803-w.\n\nHypertensive Heartbreak. Lau ES, Scirica B, Schaefer IM, Miller AL, Loscalzo J. N Engl J Med. 2021 Jun 3;384(22):2145-2152. doi: 10.1056/NEJMcps2018493.\n\nThrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. Marc S. Sabatine MD, MPH Eugene Braunwald MD. Journal of the American College of Cardiology. Volume 77, Issue 22, 8 June 2021, Pages 2822-2845.\n\nHypertensive Heartbreak. Lau ES, Vaidya A, Schaefer IM, Scirica BM. N Engl J Med. 2021 May 27;384(21):e80. doi: 10.1056/NEJMimc2031595.\n\nTransseptal left heart catheterization: birth, death, and resurrection. Braunwald E. Eur Heart J. 2021 May 25:ehab264. doi: 10.1093/eurheartj/ehab264.\n\nEfficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects – A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MS; FOURIER Study Group. Circ J. 2021 May 12. doi: 10.1253/circj.CJ-20-1051.\n\nTrends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. Roth GA, Emmons-Bell S, Alger HM, Bradley SM, Das SR, de Lemos JA, Gakidou E, Elkind MSV, Hay S, Hall JL, Johnson CO, Morrow DA, Rodriguez F, Rutan C, Shakil S, Sorensen R, Stevens L, Wang TY, Walchok J, Williams J, Murray C. JAMA Netw Open. 2021 May 3;4(5):e218828. doi: 10.1001/jamanetworkopen.2021.8828.\n\nInitial Findings From the North American COVID-19 Myocardial Infarction Registry. Garcia S, Dehghani P, Grines C, Davidson L, Nayak KR, Saw J, Waksman R, Blair J, Akshay B, Garberich R, Schmidt C, Ly HQ, Sharkey S, Mercado N, Alfonso CE, Misumida N, Acharya D, Madan M, Hafiz AM, Javed N, Shavadia J, Stone J, Alraies MC, Htun W, Downey W, Bergmark BA, Ebinger J, Alyousef T, Khalili H, Hwang CW, Purow J, Llanos A, McGrath B, Tannenbaum M, Resar J, Bagur R, Cox-Alomar P, Stefanescu Schmidt AC, Cilia LA, Jaffer FA, Gharacholou M, Salinger M, Case B, Kabour A, Dai X, Elkhateeb O, Kobayashi T, Kim HH, Roumia M, Aguirre FV, Rade J, Chong AY, Hall HM, Amlani S, Bagherli A, Patel RAG, Wood DA, Welt FG, Giri J, Mahmud E, Henry TD; Society for Cardiac Angiography and Interventions, the Canadian Association of Interventional Cardiology, and the American College of Cardiology Interventional Council. J Am Coll Cardiol. 2021 Apr 27;77(16):1994-2003. doi: 10.1016/j.jacc.2021.02.055.\n\nCardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DA. J Am Heart Assoc. 2021 Apr 22:e018673. doi: 10.1161/JAHA.120.018673.\n\nDifferentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science. Sabatine MS. JAMA Cardiol. 2021 Apr 21. doi: 10.1001/jamacardio.2021.0693.\n\nThe Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry. Lawler PR, Berg DD, Park JG, Katz JN, Baird-Zars VM, Barsness GW, Bohula EA, Carnicelli AP, Chaudhry SP, Jentzer JC, Menon V, Metkus T, Nativi-Nicolau J, Phreaner N, Sinha SS, Teuteberg JJ, van Diepen S, Morrow DA; Critical Care Cardiology Trials Network Investigators. Crit Care Med. 2021 Apr 2. doi: 10.1097/CCM.0000000000004948.\n\nEffect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. JAMA Cardiol. 2021 Apr 14. doi: 10.1001/jamacardio.2021.0660.\n\nProspective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics. Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, van der Meer P, Wernsing M, Carter K, Guo W, Zhou Y, Lefkowitz M, Gong J, Wang Y, Merkely B, Macin SM, Shah U, Nicolau JC, Braunwald E. Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.\n\nPlasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. Zelniker TA, Morrow DA, Scirica BM, Furtado JD, Guo J, Mozaffarian D, Sabatine MS, O’Donoghue ML. J Am Heart Assoc. 2021 Apr 12:e017401. doi: 10.1161/JAHA.120.017401.\n\nNonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement. Churchwell K, Antman E, Birnbaum J, Desai NR, Harrington RA, Holubowich EJ, Ivy KN, Schoeberl M, Warner JJ, White CJ, Whitsel LP, Yancy C; American Heart Association Advocacy Coordinating Committee. Circulation. 2021 Apr 12:CIR0000000000000972. doi: 10.1161/CIR.0000000000000972.\n\nCauses and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. Cavallari I, Bhatt DL, Steg PG, Leiter LA, McGuire DK, Mosenzon O, Im K, Raz I, Braunwald E, Scirica BM. J Am Coll Cardiol. 2021 Apr 13;77(14):1837-1840. doi: 10.1016/j.jacc.2021.02.030.\n\nDapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF. Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Circulation. 2021 Apr 9. doi: 10.1161/CIRCULATIONAHA.121.053659.\n\nEvaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. Smith KV, Dunning JR, Fischer CM, MacLean TE, Bosque-Hamilton JW, Fera LE, Grant JY, Zelle DJ, Matta L, Gaziano TA, MacRae CA, Scirica BM, Desai AS. J Pharm Pract. 2021 Apr 5:8971900211004840. doi: 10.1177/08971900211004840.\n\nData from Digital Health Devices Informs Ideal Cardiovascular Health. Leopold JA, Davis RB, Antman EM. J Pers Med. 2021 Mar 10;11(3):189. doi: 10.3390/jpm11030189.\n\nEfficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O’Meara E, Katova T, Ljungman CEA, Diez M, Ogunniyi MO, Langkilde AM, Sjöstrand M, Lindholm D, Bengtsson O, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Jhund PS, McMurray JJV, Køber L. JAMA Cardiol. 2021 Mar 31. doi: 10.1001/jamacardio.2021.0379.\n\nThe Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. Wise RA, Chapman KR, Scirica BM, Daoud SZ, Lythgoe D, Garcia-Gil E. Int J Chron Obstruct Pulmon Dis. 2021 Mar 18;16:689-699. doi: 10.2147/COPD.S285068.\n\nClinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, Pereira AC, Ingles J, Semsarian C, Jacoby D, Colan SD, Rossano JW, Wittekind SG, Ware JS, Saberi S, Helms AS, Ho CY. Eur Heart J. 2021 Mar 26:ehab148. doi: 10.1093/eurheartj/ehab148.\n\nSerial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Oyama K, Giugliano RP, Berg DD, Ruff CT, Jarolim P, Tang M, Murphy SA, Lanz HJ, Grosso MA, Antman EM, Braunwald E, Morrow DA. Eur Heart J. 2021 Mar 24:ehab141. doi: 10.1093/eurheartj/ehab141.\n\nSPOT the DIAGNOSIS. Verbrugge FH, Morrow DA, Vranckx P. Eur Heart J Acute Cardiovasc Care. 2021 Mar 24:zuab011. doi: 10.1093/ehjacc/zuab011.\n\nTrends in Therapy and Outcomes Associated With Respiratory Failure in Patients Admitted to the Cardiac Intensive Care Unit. Jentzer JC, Alviar CL, Miller PE, Metkus T, Bennett CE, Morrow DA, Barsness GW, Kashani KB, Gajic O. J Intensive Care Med. 2021 Mar 24:8850666211003489. doi: 10.1177/08850666211003489.\n\nEvaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. Ravvaz K, Weissert JA, Jahangir A, Ruff CT. PLoS One. 2021 Mar 18;16(3):e0248134. doi: 10.1371/journal.pone.0248134. eCollection 2021.\n\nThe Birth of Cardiology: The Golden Decade. Braunwald E. Eur Heart J. 2021 Mar 10:ehab119. doi: 10.1093/eurheartj/ehab119.\n\nRandomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Steffel J, Ruff CT, Yin O, Braunwald E, Park JG, Murphy SA, Connolly S, Antman EM, Giugliano RP. J Am Coll Cardiol. 2021 Mar 9;77(9):1197-1207.\n\nCardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SD. Diabetes Care. 2021 Mar 2:dc202492. doi: 10.2337/dc20-2492.\n\nComment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”. Giugliano RP, De Caterina R, Yamashita T. Drug Saf. 2021 Feb 24. doi: 10.1007/s40264-021-01055-1.\n\nPlasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Gencer B, Morrow DA, Braunwald E, Goodrich EL, Hilvo M, Kauhanen D, Sabatine MS, Laaksonen R, O’Donoghue ML. Eur J Prev Cardiol. 2020 Dec 29:zwaa143. doi: 10.1093/eurjpc/zwaa143.\n\nEffect of dapagliflozin on anaemia in DAPA-HF. Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Eur J Heart Fail. 2021 Feb 22. doi: 10.1002/ejhf.2132.\n\nThe efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. O’Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, Šmahelová A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SD. Diabetologia. 2021 Feb 20. doi: 10.1007/s00125-021-05399-2.\n\nIncidence, predictors and prognosis of respiratory support in non-ST segment elevation myocardial infarction. Metkus T, Miller PE, Alviar CL, Jentzer JC, van Diepen S, Katz JN, Morrow DA, Schulman S, Eid S. Eur Heart J Acute Cardiovasc Care. 2020 Apr 23:2048872620919947. doi: 10.1177/2048872620919947.\n\nOutcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20:2048872619896205. doi: 10.1177/2048872619896205.\n\nDapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF Trial. Nassif ME, Windsor SL, Tang F, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Fong MW, LaRue SJ, Umpierrez G, Hartupee J, Khariton Y, Malik AO, Ogunniyi MO, Wenger NK, Kosiborod MN. Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14352.\n\nThe Path to Universality. Braunwald E, Antman EM. Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2129.\n\nLow-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Patel PN, Giugliano RP. Glob Cardiol Sci Pract. 2020 Dec 31;2020(3):e202039. doi: 10.21542/gcsp.2020.39.\n\nTime to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjöstrand M, Solomon SD, McMurray JJV, Sabatine MS. JAMA Cardiol. 2021 Feb 17. doi: 10.1001/jamacardio.2020.7585.\n\nEfficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial. Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Bengtsson O, Jhund PS, McMurray JJV, Køber L. Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.\n\nComparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Zelniker TA, Ardissino M, Andreotti F, O’Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA. Circulation. 2021 Feb 16;143(7):673-684. doi: 10.1161/CIRCULATIONAHA.120.052216.\n\nSex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O’Donoghue ML. Circulation. 2021 Feb 16;143(7):685-695. doi: 10.1161/CIRCULATIONAHA.120.052339.\n\nPotential growth in cardiogenic shock research though an international registry collaboration: the merits and challenges of a Hub-of-Spokes model. van Diepen S, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2021 Jan 4:zuaa038. doi: 10.1093/ehjacc/zuaa038.\n\nLearning and innovation among interventional cardiologists: Insights from an international survey. Vemmou E, Nikolakopoulos I, Xenogiannis I, Karacsonyi J, Rangan BV, Garcia S, Burke MN, Jneid H, Croce KJ, Bergmark BA, Brilakis ES. Catheter Cardiovasc Interv. 2021 Feb 10. doi: 10.1002/ccd.29548.\n\nPredictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. J Am Heart Assoc. 2021 Feb 9:e017008. doi: 10.1161/JAHA.120.017008.\n\nComprehensive characterization of protein-protein interactions perturbed by disease mutations. Cheng F, Zhao J, Wang Y, Lu W, Liu Z, Zhou Y, Martin WR, Wang R, Huang J, Hao T, Yue H, Ma J, Hou Y, Castrillon JA, Fang J, Lathia JD, Keri RA, Lightstone FC, Antman EM, Rabadan R, Hill DE, Eng C, Vidal M, Loscalzo J. Nat Genet. 2021 Feb 8. doi: 10.1038/s41588-020-00774-y.\n\nDapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez MFA, O’Meara E, Nicolau JC, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV. JACC Heart Fail. 2021 Jan 28:S2213-1779(20)30704-6. doi: 10.1016/j.jchf.2020.11.009.\n\nEfficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Circ Heart Fail. 2021 Feb 3:CIRCHEARTFAILURE120007034. doi: 10.1161/CIRCHEARTFAILURE.120.007034.\n\nCardiology in 2021. Braunwald E. Eur Heart J. 2021 Feb 2:ehab025. doi: 10.1093/eurheartj/ehab025.\n\nPrevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PG; TAO investigators. Arch Cardiovasc Dis. 2021 Jan 28:S1875-2136(21)00004-8. doi: 10.1016/j.acvd.2020.09.005.\n\nEvaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment. Ting C, Rhoten M, Dempsey J, Nichols H, Fanikos J, Ruff CT. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620987900. doi: 10.1177/1076029620987900.\n\nEdoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study. de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, Grip L, Lanz H, Mercuri MF, Antman EM, Giugliano R. Am Heart J. 2021 Jan 22:S0002-8703(21)00017-X. doi: 10.1016/j.ahj.2021.01.013.\n\nRecombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design. Bonaca MP, George RT, Morrow DA, Bergmark BA, Park JG, Abuhatzira L, Vavere AL, Karathanasis SK, Jin C, She D, Hirshberg B, Hsia J, Sabatine MS. Eur Heart J Cardiovasc Pharmacother. 2021 Jan 25:pvab001. doi: 10.1093/ehjcvp/pvab001.\n\nPlasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Baris Gencer, David A Morrow, Eugene Braunwald, Erica L Goodrich, Mika Hilvo, Dimple Kauhanen, Marc S Sabatine, Reijo Laaksonen, Michelle L O’Donoghue. European Journal of Preventive Cardiology, https://doi.org/10.1093/eurjpc/zwaa143. Published: 29 December 2020.\n\nIntracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Nelson SE, Giugliano RP, Antman EM, Park JG, Norden AD, Rost NS, Silverman S, Singhal AB, Lanz HJ, Braunwald E"
    }
}